Table 3 Factors associated longitudinal changes in SUA level.

From: Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease

 

Coefficient estimate (β)

95% CI

P value

Lower limit

Upper limit

Unadjusted model

Febuxostat vs Allopurinol

−0.9207

−1.0592

−0.7822

<0.0001

Adjusted model

Febuxostat (vs Allopurinol)

−0.8699

−1.0193

−0.7206

<0.0001

PDC ≥80% (vs <80%)

−0.5423

−0.7138

−0.3708

<0.0001

Mean daily dose ≥50% (vs <50%) group mean

−0.0672

−0.24

0.1056

0.446

AKI occurrence during follow-up

0.4738

0.2676

0.6801

<0.0001

  1. PDC, proportion of days covered; ≥50% mean daily doses: febuxostat: ≥40 mg/day; allopurinol: ≥100 mg/day.
Back to article page